What is TPST's current stock price?

TPST (Tempest Therapeutics, Inc.) is currently trading at $1.86 with a market cap of $8.3M.

What sector is Tempest Therapeutics, Inc. in?

Tempest Therapeutics, Inc. (TPST) operates in the Healthcare sector, specifically in the Biotechnology industry.

InvestLog

TPST Tempest Therapeutics, Inc.

Healthcare

$1.86+2.76%ClosedMarket Cap: $8.3M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

24.74

P/S

0.00

EV/EBITDA

-0.33

DCF Value

$-0.34

FCF Yield

-319.4%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-729.9%

ROA

-401.0%

ROIC

-499.8%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-27.7M	$—
Q4 null	$0.00	$-4.0M	$—
FY null	$0.00	$-26.3M	$—
Q3 null	$0.00	$-3.5M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

0 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell

HC Wainwright & Co.Buy

2026-01-22

Trading Activity

Insider Trades

View All

Trojanowski Justinofficer: Corporate Controller

SellThu Apr 02

Maestas Nicholasofficer: Chief Financial Officer

SellThu Apr 02

Angel Matthewdirector, 10 percent owner, officer: CEO and President

BuyWed Mar 25

Angel Matthewdirector, 10 percent owner, officer: CEO and President

SellFri Feb 06

Angel Matthewdirector, 10 percent owner, officer: CEO and President

SellFri Feb 06

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

-1.69

Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.

Peers

KZR